Company

Poplar Therapeutics, Inc.

Poplar Therapeutics develops anti-IgE therapies for allergic diseases, including asthma and other IgE-mediated conditions.

About

Poplar Therapeutics develops anti-IgE medicines for allergic diseases, including asthma and other IgE-mediated conditions. Its lead program, PHB-050, targets food allergies and other atopic conditions. Founded in 2024, the company is based in Boston, US. In March 2026, it raised USD 45.00 mn in Series A funding led by Janus Henderson Investors, with participation from ArrowMark Partners, RA Capital, SR One, and Vida Ventures.

2Funding rounds

5Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in